Search PubMed⌕ Search

Biomedical subjects

M D Aceto

Publications and source records attributed to M D Aceto.

At least 73 records · Page 4Linked to original sources
PubMed1982

Opiate vs non-opiate footshock-induced analgesia (FSIA): the body region shocked is a critical factor.

Previous work has demonstrated that footshock can elicit either opiate or non-opiate analgesia. The present study has demonstrated that one critical factor determining the involvement of endogenous opioids is the body region shocked. Using 90 s shock, front paw shock produced an opiate analgesia which was significantly antagonized by as little as 0.1 mg/kg systemic naloxone and morphine tolerance. In the latter experiment, a parallel recovery of the analgesic potencies of both front paw shock and morphine was observed following 2 weeks of opiate abstinence. In contrast, hind paw shock produced a non-opiate analgesia which failed to be attenuated by 20 mg/kg systemic naloxone and showed no cross-tolerance to morphine. Since identical shock parameters were used for front paw and hind paw shock in the systemic naloxone experiments, stress per se clearly cannot be the crucial factor determining the involvement of endogenous opioids in footshock-induced analgesia. These results were discussed with respect to clinical treatments of pain which utilize somatosensory stimulation.

Analgesia↗
PubMed1982

Nicotine-induced antinociception in rats and mice: correlation with nicotine brain levels.

Nicotine was found to be potent in producing antinociception in mice and rats as measured by tail-flick latency but its action was of short duration. Nicotine's ED50 values (confidence limits) were 0.7 (0.4-1.1) and 2.0 (1.2-3.4) mg/kg in rats and mice, respectively, at the time of maximum effect. Brain levels of nicotine reached a maximum at 10 min, whereas antinociception was maximal within 2 min in rats. However, there was a good correlation between the time courses of antinociception and brain levels of nicotine in mice with both attaining maximal levels at 5 min. It was found that tachyphylaxis developed to the antinociception in rats within 10 min and lasted for up to 14 h, but tachyphylaxis did not develop to nicotine-induced antinociception in mice. The effect of nicotine appeared to be central in both rats and mice inasmuch as mecamylamine antagonized completely but hexamethonium (5 mg/kg) antagonized partially. Nicotine-induced antinociception was not blocked in either rats or mice by atropine in doses up to 10 mg/kg. Naloxone did not block nicotine in rats but did antagonize the antinociception in mice. In addition, yohimbine, a selective alpha-2 antagonist, blocked the antinociception in both species. These data implicate several different mechanisms in the antinociceptive action of nicotine.

Analgesics↗
PubMed1981

Synthesis of 4,4-ditritio-(+)-nicotine: comparative binding and distribution studies with natural enantiomer.

The preparation of 4,4-ditritio-(+)-nicotine (Vb) (specific activity 10.3 Ci/mmole)from (+)-nicotine (Ib) via (-) 4,4-dibromocotinine (IIIb) is described. Although Ib is 10-30 times less potent than (-)-nicotine (Ia) in the CNS, its binding affinity for the crude mitochondrial or nuclear fraction of whole rat brain is only three times less than that of Ia. However, distribution studies showed that the maximum brain levels of (-)-[3H] nicotine are nearly twice those of (+)-[3H]-nicotine following administration of a 2-micrograms/kg dose. Binding affinity and disposition of the stereoisomers account for a portion of the pharmacological stereospecificity of nicotine.

Animals↗
PubMed1981

Nicotine binding sites and their localization in the central nervous system.

The resolution of racemic nicotine to provide optically pure (+)-nicotine and the synthesis of radiolabeled nicotine with high specific activity have facilitated the study of nicotine binding in brain. The actions of the stereoisomers of nicotine on the central nervous system are qualitatively similar in most tests but (-)-nicotine is more potent than the unnatural (+)-isomer by 10-fold or greater. Binding of radiolabeled nicotine to brain has both saturable and nonsaturable components. Only saturable binding is affected by incubation conditions such as time, temperature, pH and ion concentration. Excess concentrations of the stereoisomers are equally effective in displacing (-)-[3H]-nicotine from brain homogenates. Nevertheless, a direct comparison of (+)-[3H]-nicotine and (-)-[3H]-nicotine binding shows that the latter has a KD three times lower than the former. (-)-[3H]-Nicotine is bound to the greatest degree in hypothalamus and hippocampus, areas that also exhibited the most stereoselectivity for nicotine. However, differences in the binding affinities of the two isomers were far less than the pharmacological stereospecificity observed.

Animals↗
PubMed1980

Discriminative stimulus properties of the optical isomers of nicotine.

Rats were trained to discriminate 200 or 400 microgram/kg (-)nicotine from saline in a two-bar operant paradigm. Dose-response relationships for optically pure (-)- and (+)nicotine as well as antagonistic effects were examined in both groups of rats. The natural isomer (-)nicotine was approximately nine-times more potent than (+)nicotine. Mecamylamine produced equal blockade of the (-)- and (+)nicotine cues. Hexamethonium and atropine were without effect. These data demonstrate the possible stereospecificity of the central nicotinic receptor that mediates the stimulus effect produced by nicotine.

Animals↗
PubMed1979

Optically pure (+)-nicotine from (+/-)-nicotine and biological comparisons with (-)-nicotine.

Optically pure (+)-nicotine has been obtained from (+/-)-nicotine using a combination of d-tartaric acid and di-p-toluoyl-l-tartaric acid. As the di-d-tartrate salt, (+)-nicotine is less potent than (-)-nicotine di-l-tartrate in producing lethality in mice, on blood pressure in anesthetized rats, and in the isolated guinea-pig ileum, indicating substantial stereospecificity for nicotine receptors. Potency ratios are 0.14, 0.06, and 0.019, respectively.

Animals↗
PubMed1978

Caffeine elicited withdrawal signs in morphine-dependent rhesus monkeys.

In the dose range of 4.0--32.0 mg/kg s.c., caffeine produced most of the signs which are commonly seen after the administration of naloxone (0.05 mg/kg s.c.) to morphine-dependent monkeys. The signs designated as lying on side or abdomen, avoiding contact, vocalizing, crawling or rolling, restlessness or pacing, tremors, retching, vomiting, coughing, vocalizing when abdomen palpated, rigid abdomen and salivation were noted. A randomized and blind experimental design, which included vehicle and positive (naloxone) controls was used. The significance of the differences between total scores for the whole syndrome was tested by the Mann-Whitney U-test. In preliminary studies in naive monkeys, caffeine was found to elicit some withdrawal signs but the results were equivocal. Na benzoate also elicited some withdrawal signs in morphine-dependent monkeys at 32.0 mg/kg s.c., but few signs were seen in naive monkeys. Caffeine was found to be approximately 10X more active than Na benzoate in inhibiting cAMP phosphodiesterase activity in a neuroblastoma cell whole homogenate assay. These results are consistent with the observations of Collier and Francis that morphine abstinence in rodents is associated with increased brain levels of cAMP.

3',5'-Cyclic-AMP Phosphodiesterases↗
PubMed1977

Potential long acting opiate antagonists: preparation, pharmacological activity, and opiate-receptor binding of N-substituted 2'-hydroxy-5-methyl-9 alpha-propyl-6,7-benzomorphans.

A homologous series of N-substituted 2'-hydroxy-5-methyl-9 alpha-propyl-6,7-benzomorphans (hydrogen to octyl inclusive, allyl, and cyclopropylmethyl) was prepared. In contradistinction to the normetazocine, normorphine, and (-)-3-hydroxymorphinan series, the N-pentyl and N-hexyl derivatives do not have the analgesic potency of the parent N-methyl compound; instead, they are narcotic antagonists with a long duration of action. All of the N-substituted 9 alpha-propylbenzomorphans, except for methyl, heptyl, and octyl, have antagonist activity. The receptor binding constants of the N-alkyl compounds are uniformly two- to threefold lower than those of the N-substituted normetazocines.

Analgesics↗
PubMed1977

3-Aminotetrahydrocarbazoles as a new series of central nervous system agents.

3-Dimethylamino-1,2,3,4-tetrahydrocarbazole, a structurally modified tryptamine, prevented amphetamine-induced stereotyped behavior in rats and prevented reserpine-induced ptosis in mice. Further study of this compound and a number of substituted derivatives indicated that either imipramine-like or chlorpromazine-like profiles were obtainable by changing substituents and their positions.

Amphetamine↗
PubMed1977

Parasympatholytic (anticholinergic) esters of the isomeric 2-tropanols. 1. Glycolates.

The 38 esters in Table I were prepared from the four isomeric 2-tropanols and a variety of racemic glycolic acids and their optical isomers. Anticholinergic activity in mice was measured in the peripheral nervous system (mydriasis) and in the central nervous system (anti-tremorine) and compared with that of atropine, scopolamine, and racemic 2-quinuclidinyl benzilate. The results (Table III) showed that several esters (such as 8, 12, 14, and 21) had significantly greater activity in both the peripheral and central nervous systems than did the reference compounds. Esters of (+)-2alpha-tropanol were more potent than those of either its epimer (-)-2beta-tropanol or its optical isomer(-)-2alpha-tropanol. Esters derived from (-)-glycolic acids were uniformly more potent than those from the (+)-glycolic acids. Esters of (+)-2alpha-notropanol and five of its N-substituted derivatives had markedly decreased activity. Peripheral/central activity ratios and time-activity profiles for five active compounds are discussed and compared with those of the reference compounds.

Animals↗
PubMed1977

The effects of naloxone and nalorphine during the development of morphine dependence in rhesus monkeys.

A randomized and blind experimental design was used to study the effects of naloxone and nalorphine on the development of morphine dependence in monkeys. The results suggest: (a) that significant dose-related differences existed for combined numbers of withdrawal symptoms times frequency of occurrences; (b) that naloxone and nalorphine were qualitatively similar; (c) antagonists are more effective as dependence develops; (d) naloxone is approximately 10 times more potent than nalorphine, and (e) vomiting was the only withdrawal sign with which ED50s could be calculated. Dependence on morphine still increases up to 9 months after the commonly accepted 90-day stabilization period as measured by the ED50 for vomiting for naloxone.

Animals↗